Entero Therapeutics 15min chart triggers Bollinger Bands Narrowing, Bearish Marubozu.

As per the 15-minute chart of Entero Therapeutics, the recent trading session has exhibited a narrowing of Bollinger Bands, accompanied by a bearish Marubozu at 10/21/2025 14:00. This suggests a decline in the magnitude of stock price fluctuations, indicating that sellers are currently dominating the market. Consequently, it is likely that bearish momentum will persist.

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) experienced a significant surge in its stock price, rising by 61% to $2.13, following the release of preclinical data that demonstrated its drug, Mira-55, outperformed morphine in pain relief and inflammation in animal tests MIRA Stock Price and Chart — NASDAQ:MIRA — TradingView^[1]. This positive news has generated considerable interest among investors, with the stock trading at a new high of $2.13.

MIRA Pharmaceuticals is a clinical development stage biopharmaceutical company that focuses on developing products for unmet medical needs in pain management, depression, PTSD, and cognitive function. The company's portfolio includes Ketamir-2 and MIRA-55, with the latter showing promising results in preclinical trials MIRA Stock Price and Chart — NASDAQ:MIRA — TradingView^[1].

The recent performance of MIRA Pharmaceuticals' stock has been mixed, with some analysts expressing optimism about the company's growth potential . However, the stock has not shown significant growth over the past week, with a monthly change of -9.59% and a year-over-year increase of 20.00% . The company's stock volatility is relatively low, with a beta coefficient of 0.92, indicating a moderate level of risk compared to the overall market .

Despite the recent surge, analysts have varying opinions on MIRA Pharmaceuticals' future price, with estimates ranging from a minimum of $3.00 to a maximum of $3.00 . The company's earnings reports indicate a loss of $0.09 per share for the last quarter, with an estimated loss of $0.08 per share for the next quarter . The company has also reduced its cash burn by 8.1% in the past year, extending its cash runway to about 16 months as of September 2023 .

Investors should carefully consider the available data and technical analysis before making investment decisions. While the recent news is positive, the stock's technical analysis shows a neutral signal for the next month, suggesting caution .